Zevra Therapeutics (Zevra Therapeutics) Cash And Cash Equivalents : $43.05 Mil (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Zevra Therapeutics Cash And Cash Equivalents?

Zevra Therapeutics's quarterly cash and cash equivalents declined from Jun. 2023 ($66.20 Mil) to Sep. 2023 ($43.27 Mil) but then stayed the same from Sep. 2023 ($43.27 Mil) to Dec. 2023 ($43.05 Mil).

Zevra Therapeutics's annual cash and cash equivalents declined from Dec. 2021 ($112.35 Mil) to Dec. 2022 ($65.47 Mil) and declined from Dec. 2022 ($65.47 Mil) to Dec. 2023 ($43.05 Mil).

Zevra Therapeutics Cash And Cash Equivalents Historical Data

The historical data trend for Zevra Therapeutics's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zevra Therapeutics Cash And Cash Equivalents Chart

Zevra Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash And Cash Equivalents

Get a 7-Day Free Trial

3.22

4.21

112.35

65.47

43.05

Zevra Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash And Cash Equivalents	Get a 7-Day Free Trial															65.47	40.18	66.20	43.27	43.05

Zevra Therapeutics Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Zevra Therapeutics (NAS:ZVRA) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Zevra Therapeutics Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Zevra Therapeutics's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Zevra Therapeutics (Zevra Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zevra Therapeutics Inc (NAS:ZVRA) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

1GDA:Germany

Address

1180 Celebration Boulevard, Suite 103, Celebration, FL, USA, 34747

Website

https://www.zevra.com

Zevra Therapeutics Inc is a rare disease company melding science, data and patient needs to create transformational therapies for diseases with limited or no treatment options. The firm's data-driven clinical, regulatory, and commercialization strategies overcome complex drug development challenges to bring much-needed therapies to patients. Its product candidate comprises Arimoclomol, orally delivered investigational product candidate for the treatment of Niemann-Pick type C (NPC). KP1077 is Zevra's lead clinical candidate being developed as a treatment for idiopathic hypersomnia (IH) and narcolepsy.

Executives

Neil F. Mcfarlane	director, officer: President and CEO	C/O RETROPHIN, INC., 12255 EL CAMINO REAL, SUITE 250, SAN DIEGO CA 92130
R. Laduane Clifton	officer: VP Fin & Corp Controller	C/O KEMPHARM, INC., 1170 CELEBRATION BLVD., #103, CELEBRATION FL 34747
Thomas Anderson	director	215 FIRST STREET, CAMBRIDGE MA 02142
Joshua Schafer	officer: CCO & EVP, Bus. Development	SHUTTLE PHARMACEUTICALS HOLDINGS, INC., ONE RESEARCH COURT, SUITE 450, ROCKVILLE MD 20850
John B Bode	director	C/O TRIBUNE PUBLISHING COMPANY, 202 W. FIRST STREET, LOS ANGELES CA 90012
Watton Corey Michael	director	22045 KAREN STREET, ELKHORN NE 68022
Douglas W Calder	director	324 S. HYDE PARK AVENUE, SUITE 350, TAMPA FL 33606
Wendy L Dixon	director
Tamara A Seymour	director	C/O SIGNAL GENETICS, INC., 5740 FLEET STREET, CARLSBAD CA 92008
Timothy J. Sangiovanni	officer: VP, Corporate Controller	C/O KEMPHARM, INC., 2500 CROSSPARK RD, STE E-126, CORALVILLE IA 52241
Matthew R Plooster	director	2656 CROSSPARK ROAD, SUITE 100, CORALVILLE IA 52241
David S Tierney	director	C/O ABLE LABORATORIES, INC., 6 HOLLYWOOD COURT, CN 1013, SOUTH PLAINFIELD NJ 07080
Richard W Pascoe	director	C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
Christopher Posner	director	C/O CARA THERAPEUTICS, INC., 4 STAMFORD PLAZA, 107 ELM STREET, 9TH FL, STAMFORD CT 06902
Travis C Mickle	director, 10 percent owner, officer: President & CEO	2656 CROSSPARK ROAD, SUITE 100, CORALVILLE IA 52241